




# Research Transparency Panel Meeting Summary

**Gilead Sciences Inc. ("Gilead")**

4th June 2024

4 – 5.30pm



# Data Access Proposal Request

## Flatiron Health UK RWD Products

- Flatiron Breast Cancer data product

## Attendees

### FLATIRON HEALTH UK

- Adam Manhi (chair)
- Emma Salib (programme manager)

### RESEARCH TRANSPARENCY PANEL

- Jennifer McCaffery (lay)
- Kaeden Bunting (lay)
- Thomas Smith (patient)
- Trishna Bharadia (patient)
- Shira Peleg Hasson (clinical)

## Conflicts of interest

No conflicts declared by panel

## Decision outcome

Approved

## Summary of discussion

- Broad agreement the proposal is well set out, with clear use cases and goals for accessing the real-world data.
- Good examples of target outputs (e.g. Lancet Journal of Oncology; ASCO conference).
- Activities following data access are clear and detailed, with explicit link between access and benefit, where specific unmet need and patient benefit is clear.
- The panel raised several comments on other aspects of the application including:
  - Expanding on detail of selected use cases i.e. Health Technology Assessment, Health Economics Outcomes Research and Market Access use case.
  - Capturing additional details in the lay summary (e.g. size of target population; mortality; current treatments available; impact of Gilead's existing therapies).
  - Providing further detail on patient engagement, including Gilead's current engagement activities and planned activity after data access granted.